- Home
- MQY vs RGNX Comparison
MQY vs RGNX Comparison
Compare MQY & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MQY | RGNX |
|---|---|---|
| Founded | 1994 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 836.1M | 761.9M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | MQY | RGNX |
|---|---|---|
| Price | $11.70 | $7.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $29.13 |
| AVG Volume (30 Days) | 184.8K | ★ 1.2M |
| Earning Date | 01-01-0001 | 03-12-2026 |
| Dividend Yield | ★ 4.73% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $161,318,000.00 |
| Revenue This Year | N/A | $128.55 |
| Revenue Next Year | N/A | $47.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 91.30 |
| 52 Week Low | $9.82 | $5.04 |
| 52 Week High | $12.52 | $16.19 |
Technical Indicators
Market Signals| Indicator | MQY | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 56.66 | 24.58 |
| Support Level | $11.65 | $10.15 |
| Resistance Level | $11.81 | $8.63 |
| Average True Range (ATR) | 0.09 | 0.79 |
| MACD | -0.01 | -0.35 |
| Stochastic Oscillator | 51.79 | 7.41 |
Price Performance
Historical ComparisonAbout MQY Blackrock MuniYield Quality Fund Inc.
Blackrock Muniyield Quality Fund Inc is a closed-end management investment company. The company's objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in Transportation, Corporate, Health, Utilities, Education, Housing, and other sectors.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.